Lipocine (LPCN) Share-based Compensation (2012 - 2025)
Lipocine's (LPCN) quarterly Share-based Compensation came in at $245000.0 in Q3 2025, up 127.07% YoY from $107894.0 in Q3 2024, and up 275.74% on a QoQ basis from $65205.0 in Q2 2025.
Lipocine (LPCN) Share-based Compensation (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Share-based Compensation data on file, last reported at $245000.0 in Q3 2025.
- Quarterly Share-based Compensation rose 127.07% year-over-year to $245000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $245000.0 (down 47.07% YoY) and the FY2024 annual result came in at $440000.0, down 32.77% from the prior year.
- Share-based Compensation grew to $245000.0 in Q3 2025, from $65205.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $245000.0 in Q3 2025 to a low of $65205.0 in Q2 2025.
- A 5-year average of $141358.9 and a median of $153438.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation tumbled 68.39% — and 2025, when it jumped 127.07%.
- Tracing LPCN's Share-based Compensation over 5 years: stood at $154689.0 in 2021, then rose by 6.76% to $165140.0 in 2022, then decreased by 7.09% to $153438.0 in 2023, then slumped by 35.13% to $99535.0 in 2024, then soared by 146.14% to $245000.0 in 2025.
- The last three Share-based Compensation figures came in at $245000.0 (Q3 2025), $65205.0 (Q2 2025), and $71002.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 245,000.00 |
| Sep 30, 2025 | 245,000.00 |
| Jun 30, 2025 | 65,205.00 |
| Jun 30, 2025 | 65,205.00 |
| Mar 31, 2025 | 71,002.00 |
| Mar 31, 2025 | 71,002.00 |
| Dec 31, 2024 | 99,535.00 |
| Dec 31, 2024 | 99,535.00 |
| Sep 30, 2024 | 107,894.00 |
| Sep 30, 2024 | 107,894.00 |
| Jun 30, 2024 | 102,265.00 |
| Jun 30, 2024 | 102,265.00 |
| Mar 31, 2024 | 99,306.00 |
| Mar 31, 2024 | 99,306.00 |
| Dec 31, 2023 | 153,438.00 |
| Dec 31, 2023 | 153,438.00 |
| Sep 30, 2023 | 158,090.00 |
| Sep 30, 2023 | 158,090.00 |
| Jun 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 165,000.00 |